Depletion of KDM6A by either knockout or shRNAs caused no changes in the expression of BCR-ABL or its phosphorylation at Tyr177 (Figure 1F), indicating that protection of CML cells against imatinib by KDM6A is not due to alterations in the expression or activity of BCR-ABL. This evidence concerns the gene KDM6A and chronic myelogenous leukemia, BCR-ABL1 positive.